Breadcrumb

[A09-05] Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

Overview

Overview

Commission: Commission awarded on 2009-12-18 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of the final report  [PDF, 101 kB]Further documents
Contact address:to the contact form
Linked projects: [A05-19A] Cholinesterase inhibitors in Alzheimer's disease
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2012-04-02 Executive summary of the final report 101 kBPDFdownload file
2012-04-02 Final report (German version) 2 MBPDFdownload file
2012-04-02 Documentation and evaluation on the preliminary report (German version) 6 MBPDFdownload file
2011-07-25 Executive summary of the preliminary report (German version) 139 kBPDFdownload file
2011-07-25 Preliminary report (German version) 2 MBPDFdownload file
2010-08-16 Report plan version 1.0 (German version) 137 kBPDFdownload file
2010-08-16 Documentation and appraisal of comments on the preliminary report plan (German version) 2 MBPDFdownload file
2010-04-19 Preliminary report plan (German version) 141 kBPDFdownload file


At a glance

Accompanying information

Executive summary of the final report

  File-Icon  Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine [PDF, 101 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealthonline.org.

Alzheimer's disease: How effective are cholinesterase inhibitors?

Press releases

2012-04-02 Galantamine and rivastigmine patches: positive influence on cognition possible



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close